| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.028 | 0.9 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.068 | 0.9 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.9 |